

Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Medroxyprogesterone (Sayana Press®)		
Indication under review	Contraception		
Policy No:	APC 126		
Date of Issue:	March 2016		
Review Date:	March 2019		
Policy Statement: Sayana Press® is recommended as a treatment option for contraception			
Traffic Light Status	Green		
Key Points considered:			
<ul style="list-style-type: none"> • The APC supported the evidence of efficacy and safety for this treatment. • This treatment is subcutaneous and can be given by self-administration or by a HCA thereby freeing up nurse appointments. • Treatment is similar in cost to the IM depot injection. • Treatment can be used in obese patients. 			
Reference			
<p>1. Public Assessment Report Sayana 104mg/0.65ml Suspension for Injection Pfizer Limited. Medicines and Healthcare products Regulatory Agency. http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con126147.pdf</p> <p>2. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. <i>Contraception</i> 2004; 70(4): 269-75.</p> <p>3. Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs intramuscular DMPA: a 2 year randomized study of contraceptive efficacy and bone mineral density. <i>Contraception</i> 2009; 80(1): 7-17.</p> <p>4. Jain J, Dutton C, Nicosia A, Wajszczuk C, Bode FR, Mishell DR Jr. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. <i>Contraception</i> 2004; 70(1):11-8.</p> <p>5. Segall-Gutierrez P, Taylor D, Liu X, Stanczyk F, Azen S, Mishell DR Jr. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. <i>Contraception</i> 2010; 81(6):487-95.</p> <p>6. Prabhakaran S, Sweet A. Self administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability. <i>Contraception</i> 2012; 85(5):453-7.</p> <p>7. Cameron ST, Glasier A, Johnstone A. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception. <i>Contraception</i> 2012; 85(5):458-64.</p> <p>8. Lakha F, Henderson C, Glasier A. The acceptability of self-administration of subcutaneous Depo-Provera. <i>Contraception</i> 2005;72(1):14-8</p> <p>9. Faculty of Sexual & Reproductive Healthcare Clinical Guidance. Progestogen-only injectable contraception. Clinical Effectiveness Unit; November 2008. http://www.fsrh.org/pdfs/CEUGuidanceProgestogenOnlyInjectables09.pdf</p> <p>10. The Department of Health. Immunisation Procedures Chapter 4. The Green Book Updated June 2012. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/147915/Green-Book-Chapter-4.pdf</p>			
Date taken to APC:	2 nd March 2016		
Date Ratified by MMC on Behalf of the Board:	23 rd March 2016		

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

Brown	Green	Amber	Red
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only